Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Relistor Methylnaltrexone bromide Constipation, Opioid-induced Do not list Complete
Relpax Eletriptan hydrobromide Migraine Do not list Complete
Remicade Infliximab Ulcerative Colitis Do not list Complete
Remodulin Treprostinil sodium Pulmonary arterial hypertension (NYHA Class III and IV patients) Do not list Complete
Remodulin Treprostinil sodium Pulmonary arterial hypertension (NYHA Class III and IV patients) List with clinical criteria and/or conditions Complete
Remsima infliximab Rheumatoid arthritis Reimburse with clinical criteria and/or conditions Complete
Remsima Infliximab Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis Withdrawn
Remsima infliximab Ulcerative Colitis Reimburse with clinical criteria and/or conditions Complete
Remsima infliximab Crohn’s disease Reimburse with clinical criteria and/or conditions Complete
Renflexis infliximab rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis Reimburse with clinical criteria and/or conditions Complete